XOMAP.PFD (XOMA Royalty) ROCE % : -25.77% (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is XOMA Royalty ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. XOMA Royalty's annualized ROCE % for the quarter that ended in Sep. 2024 was -25.77%.

XOMA Royalty ROCE % Historical Data

The historical data trend for XOMA Royalty's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Royalty ROCE % Chart

XOMA Royalty Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-0.10

13.65

12.27

-11.92

-23.11

XOMA Royalty Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-18.97	-47.58	-9.64	36.19	-25.77

XOMA Royalty ROCE % Calculation

XOMA Royalty's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-40.262	/	( ( (140.382 - 6.818)	+	(234.301 - 19.499) )	/ 2 )
	=	-40.262	/	( (133.564	+	214.802)	/ 2 )
	=	-40.262	/	174.183
	=	-23.11 %

XOMA Royalty's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	-55	/	( ( (243.28 - 18.615)	+	(223.34 - 21.134) )	/ 2 )
	=	-55	/	( ( 224.665	+	202.206 )	/ 2 )
	=	-55	/	213.4355
	=	-25.77 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

XOMA Royalty (NAS:XOMAP.PFD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

XOMA Royalty ROCE % Related Terms

Thank you for viewing the detailed overview of XOMA Royalty's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

XOMA Royalty Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Royalty Corp (NAS:XOMAP.PFD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

XOMAO.PFD:USA XOMA:USA 0M26:UK X0M1:Germany

Address

2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608

Website

https://www.xoma.com

XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.